

March 26, 2018

To whom it may concern:

We at San Francisco Edit (www.sfedit.net) certify that on March 26, 2018 we edited the manuscript "Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence" by Maria Lia Scribano. We certify the version we edited contains correct English and was edited for language usage, grammar, spelling, and punctuation by a Ph.D. scientist who is a native English speaker.

Please note that the author has the ability to accept or reject our suggestions and changes; therefore, we are not responsible for any additions or deletions made to the manuscript after our editing.

Sincerely,

A handwritten signature in black ink, appearing to read "P. Kretchmer", is positioned above the printed name.

Paul Kretchmer. Ph.D.
Managing Director